Diagnostic value of fourth-generation iterative reconstruction algorithm with low-dose CT protocol in assessment of mesorectal fascia invasion in rectal cancer: comparison with magnetic resonance

Ippolito, Davide; Drago, Silvia Girolama; Franzesi, Cammillo R Talei; Casiraghi, Alessandra; Sironi, Sandro

doi:10.1007/s00261-017-1138-z

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For most CRC, CT is the routinely used imaging modality for tumor diagnosis, tumor staging, identifying patients who require neo-adjuvant therapy, and assessing treatment response [43][44][45][46]. Recently, some reports have found that new generation CT scanners can offer high spatial resolution images with reliable rectal staging with low dose of radiation, particularly useful in patients who have contraindication to MRI [47,48]. If used in conjunction with KRAS mutation status, CT may potentially be used as a noninvasive biomarker for deciding appropriate therapy selection and also predict patient prognosis.…”

Section: Discussionmentioning

confidence: 99%

Imaging features associated with survival outcomes among colorectal cancer patients with and without KRAS mutation

Promsorn

Chadbunchachai

Somsap

et al. 2021

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background Mutations in Kirsten rat sarcoma proto-oncogene (KRAS) have been shown to be associated with advanced-stage colorectal cancer (CRC), negative disease outcomes, and poor response to treatment. The purpose of this study was to investigate which CT features are biomarkers for KRAS gene mutation and impact the survival outcomes of colorectal cancer patients. Results Of the 113 CRC patients included in the study, 46 had KRAS mutations (40.71%) and 67 had no mutations (59.29%). Regional lymph node necrosis was the only imaging feature significantly associated with KRAS mutation (P = 0.011). Higher T staging and liver, lung, and distant metastasis were prognostic factors for CRC (P = 0.014, P < 0.001, P = 0.022, P < 0.001, respectively). There were no significant differences in overall survival between patients with KRAS mutations and those without (P = 0.159). However, in patients with no KRAS mutation, those with CRC on the left side had a significantly higher rate of survival than those with CRC on the right (P = 0.005). Conclusion Regional lymph node necrosis may be an imaging biomarker of CRC with KRAS mutation, possibly indicating poor prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Imaging features associated with survival outcomes among colorectal cancer patients with and without KRAS mutation

Promsorn

Chadbunchachai

Somsap

et al. 2021

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

show abstract

“…The possibility to include with new CT scanner systems dose-intensive perfusion sequences in CT staging protocols without exceeding dose reference values is very encouraging given accuracy and validity of the perfusion analysis. Given the fact, that there are even attempts of the CT community to overtake T staging 36 which is to date clearly regarded as the holy grail of MR in rectal cancer imaging, the idea of a one-stop-shop CT approach in rectal cancer patients quickly comes to one’s mind. However, as dose recommendations for standard CT examinations are constantly updated and national CT dose reference values have been only recently lowered dramatically 22 , 37 , further optimization of perfusion CT protocols taking e.g.…”

Section: Limitationsmentioning

confidence: 99%

Variability and Reproducibility of 3rd-generation dual-source dynamic volume perfusion CT Parameters in Comparison to MR-perfusion Parameters in Rectal Cancer

Sudarski

Henzler

Floss

et al. 2018

Sci Rep

View full text Add to dashboard Cite

To compare in patients with untreated rectal cancer quantitative perfusion parameters calculated from 3rd-generation dual-source dynamic volume perfusion CT (dVPCT) with 3-Tesla-MR-perfusion with regard to data variability and tumour differentiation. In MR-perfusion, plasma flow (PF), plasma volume (PV) and mean transit time (MTT) were assessed in two measurements (M1 and M2) by the same reader. In dVPCT, blood flow (BF), blood volume (BV), MTT and permeability (PERM) were assessed respectively. CT dose values were calculated. 20 patients (60 ± 13 years) were analysed. Intra-individual and intra-reader variability of duplicate MR-perfusion measurements was higher compared to duplicate dVPCT measurements. dVPCT-derived BF, BV and PERM could differentiate between tumour and normal rectal wall (significance level for M1 and M2, respectively, regarding BF: p < 0.0001*/0.0001*; BV: p < 0.0001*/0.0001*; MTT: p = 0.93/0.39; PERM: p < 0.0001*/0.0001*), with MR-perfusion this was true for PF and PV (p-values M1/M2 for PF: p = 0.04*/0.01*; PV: p = 0.002*/0.003*; MTT: p = 0.70/0.27*). Mean effective dose of CT-staging incl. dVPCT was 29 ± 6 mSv (20 ± 5 mSv for dVPCT alone). In conclusion, dVPCT has a lower data variability than MR-perfusion while both dVPCT and MR-perfusion could differentiate tumour tissue from normal rectal wall. With 3rd-generation dual-source CT dVPCT could be included in a standard CT-staging without exceeding national dose reference values.

show abstract

Imaging and Management of Rectal Cancer

Arya

Sen

Saklani

et al. 2020

Seminars in Ultrasound, CT and MRI

View full text Add to dashboard Cite

Diagnostic value of fourth-generation iterative reconstruction algorithm with low-dose CT protocol in assessment of mesorectal fascia invasion in rectal cancer: comparison with magnetic resonance

Abstract: Low-dose protocol combined with iDose4 reconstruction algorithm offers high-quality images, obtaining significant radiation dose reduction, useful in the evaluation of MRF involvement in rectal cancer patients.

Cited by 3 publications

References 29 publications

Imaging features associated with survival outcomes among colorectal cancer patients with and without KRAS mutation

Imaging features associated with survival outcomes among colorectal cancer patients with and without KRAS mutation

Variability and Reproducibility of 3rd-generation dual-source dynamic volume perfusion CT Parameters in Comparison to MR-perfusion Parameters in Rectal Cancer

Imaging and Management of Rectal Cancer

Contact Info

Product

Resources

About